Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Tamiflu Ad Letter Continues FDA Scrutiny Of New Flu Drugs

Executive Summary

Roche's claim that Tamiflu "reduces the duration of the flu" overstates the efficacy of the drug, FDA maintained in an April 14 letter to Roche.

You may also be interested in...



Roche Tamiflu Celebrity Endorsement Ad Challenged By FDA

Celebrity endorsements of prescription drugs must be carefully qualified to avoid overstating efficacy, FDA told Roche in a letter objecting to a radio broadcast commercial for the flu therapy Tamiflu (oseltamivir)

Roche Tamiflu Celebrity Endorsement Ad Challenged By FDA

Celebrity endorsements of prescription drugs must be carefully qualified to avoid overstating efficacy, FDA told Roche in a letter objecting to a radio broadcast commercial for the flu therapy Tamiflu (oseltamivir)

Roche Xenical Patient Compliance Could Increase With New DTC Campaign

Roche will attempt to increase patient compliance for its obesity drug Xenical through a multi-faceted direct-to-consumer campaign.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS035976

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel